title: Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor.
abstract: The human histamine H(4)-receptor (hH(4)R) possesses high constitutive activity and, like the human H(1)-receptor (hH(1)R), is involved in the pathogenesis of type-I allergic reactions. The study aims were to explore the value of dual H(1)/H(4)R antagonists as antiallergy drugs and to address the question of whether H(1)R ligands bind to hH(4)R. In an acute murine asthma model, the H(1)R antagonist mepyramine and the H(4)R antagonist 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methyl-piperazine (JNJ 7777120) exhibited synergistic inhibitory effects on eosinophil accumulation in the bronchoalveolar lavage fluid. At the hH(4)R expressed in Sf9 insect cells, 18 H(1)R antagonists and 22 H(1)R agonists showed lower affinity to hH(4)R than to hH(1)R as assessed in competition binding experiments. For a small number of H(1)R antagonists, hH(4)R partial agonism was observed in the steady-state GTPase assay. Most compounds were neutral antagonists or inverse agonists. Twelve phenylhistamine-type hH(1)R partial agonists were also hH(4)R partial agonists. Four histaprodifen-type hH(1)R partial agonists were hH(4)R inverse agonists. Dimeric histaprodifen was a more efficacious hH(4)R inverse agonist than the reference compound thioperamide. Suprahistaprodifen was the only histaprodifen acting as hH(4)R partial agonist. Suprahistaprodifen was docked into the binding pocket of inactive and active hH(4)R models in two different orientations, predominantly stabilizing the active state of hH(4)R. Collectively, the synergistic effects of H(1)R and H(4)R antagonists in an acute asthma model and the overlapping interaction of structurally diverse H(1)R ligands with hH(1)R and hH(4)R indicate that the development of dual H(1)R/H(4)R antagonists is a worthwhile and technically feasible goal for the treatment of type-I allergic reactions.
authors.affiliation: Department of Pharmacology, School of Pharmacy, University of Regensburg, Regensburg, Germany.
authors.forename: Karl-Friedrich
authors.initials: KF
authors.lastname: Deml
authors.forename: Silke
authors.initials: S
authors.lastname: Beermann
authors.forename: Detlef
authors.initials: D
authors.lastname: Neumann
authors.forename: Andrea
authors.initials: A
authors.lastname: Strasser
authors.forename: Roland
authors.initials: R
authors.lastname: Seifert
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D002478:Cells, Cultured; D005260:Female; D006632:Histamine / Q000031:analogs & derivatives / Q000378:metabolism; D017442:Histamine Agonists / Q000378:metabolism*; D006634:Histamine H1 Antagonists / Q000378:metabolism*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008958:Models, Molecular; D008969:Molecular Sequence Data; D011485:Protein Binding / Q000502:physiology; D043562:Receptors, G-Protein-Coupled / Q000235:genetics / Q000378:metabolism*; D011968:Receptors, Histamine / Q000235:genetics / Q000378:metabolism*; D000074040:Receptors, Histamine H4; D017386:Sequence Homology, Amino Acid; D018411:Spodoptera
chemical_list: C418607:HRH4 protein, human; D017442:Histamine Agonists; D006634:Histamine H1 Antagonists; D043562:Receptors, G-Protein-Coupled; D011968:Receptors, Histamine; D000074040:Receptors, Histamine H4; C118994:histaprodifen; D006632:Histamine